Wegovy® providers &
prescriptions in Estero, FL
Verified Wegovy providers in Estero, FL. Checked against the NPI registry, never ranked by who pays us.[7]
Find an Wegovy provider in Florida.
Every entry is checked against the federal NPI registry. We do not accept payment for placement.
How to get Wegovy in Estero.
29 GLP-1 prescribers and 7 local resource types are on record for Estero, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.
Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]
In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]
Community health · CDC
Weight & metabolic health in Estero
Estero, Florida has a population of 36,939 people. The adult obesity rate in Estero is an age-adjusted estimate of 27.3%, 2.3 percentage points below the Florida state rate of 29.6%. Diagnosed diabetes reaches 8.1% of adults in Estero. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 17.8% of adults in Estero.
- of Estero adults have obesity
- 27.3%
- diagnosed diabetes
- 8.1%
- no regular physical activity
- 17.8%
Age-adjusted estimates for Estero, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Estero.
Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Estero, FL, ordered as the registry lists them, never by who pays us.
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
2630 W Broward Blvd Ste 203
13206 Lazzaro Ct
10600 Chevrolet Way Ste 229
What the trials actually showed.
We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Wegovy (semaglutide) prescribers and clinics, never ranked by who pays us.
Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]